EMA Authorised: Volibris (ambrisentan) — GlaxoSmithKline Trading Services Limited

View source ↗

Summary

EMA authorised Volibris (ambrisentan) for pulmonary arterial hypertension; the marketing authorisation holder is GlaxoSmithKline Trading Services Limited.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• Volibris (ambrisentan)

Snippet

Status: Authorised. Therapeutic area: Hypertension, Pulmonary. MAH: GlaxoSmithKline Trading Services Limited. Decision date: 16/04/2026